¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes - A single centre retrospective analysis of experience at an ENETS Centre of Excellence

Endocrine Abstracts（2023）

引用 0|浏览8

暂无评分

摘要

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

查看译文

关键词

paragangliomas,metastatic/inoperable phaeochromocytomas,sdhx mutation,lu-dotatate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes - A single centre retrospective analysis of experience at an ENETS Centre of Excellence